These findings are consistent with earlier reports that cardiac injury biomarkers are associated with an increased risk of COVID-19 mortality.7,10 Elevated levels of cardiac troponin I and (NT-pro)BNP, CK-MB, and MYO are also associated with more severe symptoms and disease progression.11–14 Our larger sample size helped to better define and to improve the performance characteristics of these biomarkers for COVID-19, which manifest with widely divergent outcomes from full recovery to rapid death. The gene discussed is NPPB; the disease is COVID-19.